Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00359723 · ClinicalTrials.gov registry record · Phase 2
Methylphenidate and Parkinson's Disease
A Phase 2 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00359723 is a Phase 2 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 13 participants.
The verdict
NCT00359723, a Phase 2 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine if methylphenidate (MPD), a drug marketed in the U.S. to treat hyperactivity and narcolepsy, added to levodopa, will increase the beneficial effects of levodopa without bothersome side effects in people with Parkinson's disease (PD).
Interventions
- DRUG methylphenidate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2004-07 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00359723
The ClinicalTrials.gov registry entry for NCT00359723 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which methylphenidate is the first listed.
NCT00359723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00359723 about?
NCT00359723 is a clinical study titled "Methylphenidate and Parkinson's Disease". The purpose of this trial is to determine if methylphenidate (MPD), a drug marketed in the U.S. to treat hyperactivity and narcolepsy, added to levodopa, will increase the beneficial effects of levodopa without bothersome side effects in people with Parkinson's disease (PD).
What is the current status of trial NCT00359723?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2004-07. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00359723?
The interventions under investigation include: methylphenidate (DRUG).
Who is sponsoring clinical trial NCT00359723?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.